Cytokinetics 6032 – Evaluation of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (H-53299)

Aficamten is a next-generation small molecule cardiac myosin inhibitor being developed as a chronic, oral treatment for participants with hypertrophic cardiomyopathy (HCM). Aficamten is designed to reduce the hypercontractility that underlies the pathophysiology of HCM. Selective inhibition of cardiac myosin with aficamten may yield potential advantages over current therapies for obstructive hypertrophic cardiomyopathy (oHCM) by directly reducing myocardial hypercontractility and addressing the fundamental cause of this sarcomeric disease.

This is the second Phase 3 trial of aficamten in participants with symptomatic oHCM. CY 6032 is a Phase 3 trial designed to evaluate the effect of aficamten compared with beta-blocker (metoprolol succinate [metoprolol]) on exercise capacity, heart failure symptoms, cardiac structure and function, and safety and tolerability in participants with symptomatic oHCM. The overall objective of this active comparator trial is to evaluate the safety and efficacy of aficamten as: 1) first-line therapy for participants who are recently diagnosed and/or treatment naïve; or as 2) monotherapy for participants previously receiving standard of care (SOC) medical therapy for symptomatic oHCM.